Analysts Anticipate Amedisys Inc (AMED) Will Post Earnings of $0.53 Per Share
Wall Street brokerages forecast that Amedisys Inc (NASDAQ:AMED) will post earnings of $0.53 per share for the current quarter, Zacks reports. Five analysts have made estimates for Amedisys’ earnings. The lowest EPS estimate is $0.52 and the highest is $0.54. Amedisys reported earnings of $0.36 per share in the same quarter last year, which indicates a positive year over year growth rate of 47.2%. The firm is scheduled to announce its next quarterly earnings results on Thursday, November 2nd.
According to Zacks, analysts expect that Amedisys will report full-year earnings of $2.22 per share for the current financial year, with EPS estimates ranging from $2.20 to $2.24. For the next year, analysts forecast that the firm will report earnings of $2.45 per share, with EPS estimates ranging from $2.36 to $2.58. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that follow Amedisys.
Amedisys (NASDAQ:AMED) last announced its earnings results on Wednesday, July 26th. The health services provider reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.12. The business had revenue of $378.80 million for the quarter, compared to analysts’ expectations of $380.80 million. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. The business’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period last year, the firm posted $0.42 earnings per share.
A number of research analysts have recently weighed in on the company. BidaskClub raised Amedisys from a “sell” rating to a “hold” rating in a report on Friday. Mizuho lowered Amedisys from a “buy” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a report on Wednesday, July 26th. Royal Bank Of Canada reissued a “hold” rating and issued a $56.00 price objective on shares of Amedisys in a report on Monday, June 5th. Stephens upped their target price on Amedisys from $50.00 to $54.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 4th. Finally, Benchmark Co. restated a “hold” rating and issued a $57.00 target price (up previously from $50.00) on shares of Amedisys in a research note on Wednesday, May 3rd. Six analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $56.50.
In other news, insider David B. Pearce sold 1,000 shares of the company’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $50.00, for a total value of $50,000.00. Following the sale, the insider now owns 10,488 shares in the company, valued at $524,400. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bruce D. Perkins bought 500 shares of the stock in a transaction dated Thursday, May 25th. The stock was bought at an average price of $59.69 per share, for a total transaction of $29,845.00. Following the purchase, the director now directly owns 13,331 shares of the company’s stock, valued at $795,727.39. The disclosure for this purchase can be found here. 2.80% of the stock is owned by corporate insiders.
Several hedge funds have recently modified their holdings of AMED. Riverhead Capital Management LLC increased its position in shares of Amedisys by 75.5% in the second quarter. Riverhead Capital Management LLC now owns 1,931 shares of the health services provider’s stock worth $121,000 after buying an additional 831 shares in the last quarter. Federated Investors Inc. PA increased its position in shares of Amedisys by 2.3% in the second quarter. Federated Investors Inc. PA now owns 1,929 shares of the health services provider’s stock worth $122,000 after buying an additional 44 shares in the last quarter. Ameritas Investment Partners Inc. acquired a new position in shares of Amedisys during the first quarter worth about $123,000. State of Alaska Department of Revenue increased its position in shares of Amedisys by 2.3% in the first quarter. State of Alaska Department of Revenue now owns 3,080 shares of the health services provider’s stock worth $157,000 after buying an additional 70 shares in the last quarter. Finally, CIBC Asset Management Inc acquired a new position in shares of Amedisys during the second quarter worth about $230,000. Hedge funds and other institutional investors own 99.80% of the company’s stock.
Amedisys (AMED) opened at 48.88 on Friday. Amedisys has a 12 month low of $34.58 and a 12 month high of $65.91. The stock has a market capitalization of $1.66 billion, a PE ratio of 41.78 and a beta of 0.89. The firm has a 50-day moving average price of $56.08 and a 200 day moving average price of $54.19.
Amedisys Company Profile
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.